Product Description
Dapansutrile (OLT1177) acts as a NLRP3 inflammasome inhibitor. It is a clinical candidate that is being developed by Olatec Therapeutics. Inhibition of the NLRP3 inflammasome reduces maturation of the pro-inflammatory, disease-associated cytokines IL-1beta and IL-18 [1]. Immunoprecipitation and FRET analysis indicates that OLT1177 inhibits inflammasome oligomerization by blocking NLRP3-ASC, and NLRP3-caspase-1 interaction, but may also directly target NLRP3 (as assessed by inhibition of recombinant NLRP3 ATPase activity by dapansutrile). (Sourced from: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10056)
Mechanisms of Action: NLRP3 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Olatec
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: France, Israel, Netherlands, Spain, Switzerland, United Kingdom, United States
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Pain|Arthralgia|Gout
Phase 2: Inflammation|Melanoma|Parkinson's Disease|Type 2 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07157735 |
DAPA-PD | P2 |
Not yet recruiting |
Inflammation|Parkinson's Disease |
2027-08-01 |
2% |
2025-09-06 |
Primary Endpoints|Treatments |
NCT06047262 |
Dapan-Dia | P2 |
Recruiting |
Type 2 Diabetes |
2026-07-31 |
50% |
2024-07-05 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Trial Status |
NCT04971499 |
Pro00108864 | P2 |
Recruiting |
Melanoma |
2026-04-30 |
12% |
2025-06-03 |
|
NCT05658575 |
OLT1177-08 | P3 |
Recruiting |
Arthralgia|Acute Pain |
2026-07-31 |
11% |
2025-12-16 |
|
2024-518844-20-00 |
OLT1177-08 | P3 |
Recruiting |
Gout |
2025-09-30 |
2025-05-02 |
Treatments |